Index

5HT2A receptors 168
acetylcholinesterase inhibitors (AchEI) 175
see also cholinergic targets
ACT see Assertive Community Treatment
acute polymorphic delusional psychosis 5
acute psychotic phase 163
AD see Alzheimer’s disease
ADHD see attention deficit hyperactivity disorder
adoption studies 110–11
adverse effects, classification systems 13–14
affective disorders 188–9
agitated dementia praecox 3
Alzheimer’s disease (AD) 174–5
Ambiguous Intentions Hostility Questionnaire 78
American Psychiatric Association (APA) see Diagnostic and Statistical Manual
amino acid targets 171
amisulpride 146–8, 168
AMPA receptor modulators 172
antidepressants 148
antipsychotics see individual drugs; pharmacological interventions; anxiety disorders 196
APA (American Psychiatric Association) see Diagnostic and Statistical Manual
appraisal 189–90, 191–2
aripiprazole 146–9, 163, 165
asenapine 169
Assertive Community Treatment (ACT) 226
attention deficit hyperactivity disorder (ADHD) 127–8
attenuated positive psychotic symptoms 145
attributional bias 78, 190
Attributional Style Questionnaire 78
autism 4, 21, 126–8
Awareness of Social Inferences Test 79
balanced care 225
biopsychosocial vulnerability 186–7
bipolar affective disorder 18
bipolar dichotomy 20
bipolar disorder 19–20, 112–13, 123–5
Bleuler’s group of schizophrenias 4
borderline learning disability 120
brief limited intermittent psychotic symptoms 144
Brodman criteria 45–6
burden of care 218–19
CAARMS see Comprehensive Assessment of the At-Risk Mental State
caregivers 218–20
case management (CM) 226–7
catatonia 3, 6
catechol O-methyltransferase (COMT) 169, 173
categories, classification systems 23
CATIE see Clinical Antipsychotic Trials of Intervention Effectiveness
CBT see cognitive behaviour therapy
cellular disturbances
hippocampus and entorhinal cortex 43–5
neurodevelopmental disturbances and neurodegenerative hypothesis 46–8
pathophysiology of schizophrenia 31–50
prefrontal and temporal cortex 45–6
thalamus 46
cholinergic targets 174–6
chromosomal abnormalities 120–1
circular dementia praecox 3
classification systems 1–25
Bleuler’s group of schizophrenias 4
categories and dimensions 23
clinical relevance and cognitive ease of use 14–15
comorbidities 2, 14
criterion validity 19–21
INDEX

classification systems (Cont.)
cultural aspects 21
diagnostic criteria 4, 13–21
diseases and broad syndromes 22–3
derphenotypes 23–4
genetic and environmental contributions 19–21
Kraepelin’s clinical forms 3–4
Leonhard’s endogenous psychoses 5
origin and evolution of schizophrenia 2–9
pathophysiology of schizophrenia 20
positive impact and unintended adverse effects 13–14
post-Kraepelinian and post-Bleulerian subtypes and dichotomies 5–7
predictive validity 17–19
procedural criteria 17
psychoses in French psychiatry 5
reliability 16
revisions of classifications 22
schizophrenia spectrum concept 8
Schneider’s first-rank symptoms 6, 10
statistically derived clusters and symptom dimensions 8–9
stigma 21
utility in research 15–16
validity 16–21
see also Diagnostic and Statistical Manual; International Classification of Diseases
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) 94, 162
clinical genetic testing 133–4
clinical relevance 14–15
clinical staging model 150–2
clozapine 33, 50, 163, 167–8, 169, 173, 197
CM see case management
CNTRICS see Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia
CNV see copy number variants
cognition-enhancing drugs 72–3
cognitive behaviour therapy (CBT) 146, 185–203
affect roles 188–9
anomalous experiences 191–2
appraisal/reappraisal 186, 189–90, 191–2
attributional style 191, 198
behaviour roles 192
biopsychosocial vulnerability 186–7
case example 194–6
collaborative approaches 193–4
core intervention components 189, 201
early recognition of risk 141–2
efficacy 198–201
future developments 201–2
historical development 201
insight and illness appraisals 192
life events 187–8
low intensity approaches 202
management of schizophrenia 163–6
models of psychosis 186–92
normalisation 193
outcome analyses 197–201
pharmacological interventions 170–1
positive symptoms 189
reasoning biases 190–1
rehabilitation 227–8
schematic beliefs 187–8
schizophrenia 193–6
schizophrenia-spectrum psychosis 186
technique and characteristics 185–6
training and competence 201–2
cognitive ease of use 14–15
cognitive impairments as targets 170–1
Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) 74
collaborative approaches 193–4
colony stimulating factor 2 receptor alpha (CSF2RA) 123
common risk alleles 132
common risk syndrome 152
community burden 219–20
community integration 236
comorbidities
classification systems 2, 14
Comprehensive Assessment of the At-Risk Mental State (CAARMS) 145
costs of treatment 225
criterion validity 19–21
Crohn’s disease 126
cultural aspects 21
comorbidities
Cost Utility of the Latest Antipsychotics in Schizophrenia (CUtLASS) 162
costs of treatment 225
criterion validity 19–21
Crohn’s disease 126
CSF2RA see colony stimulating factor 2 receptor alpha
cultural aspects 21
CUtLASS see Cost Utility of the Latest Antipsychotics in Schizophrenia
cycloid psychoses 5–6
D-amino acid oxidase activator (DAOA) 115
D2/3 receptors see dopamine receptors
DAT see dopamine transporter
data-gathering biases 190
INDEX

deficit-nondeficit schizophrenia 7
deinstitutionalisation 218, 226, 233
dementia 162, 175
dementia praecox 3–5, 32, 68
density studies 44
depression
cognitive behaviour therapy 186, 188
neurocognitive impairments 71
depressive dementia praecox 3
Diagnostic and Statistical Manual (DSM-III) 8, 19
Diagnostic and Statistical Manual (DSM-IV) 1–2, 9–25
categories and dimensions 23
clinical relevance and cognitive ease of use 14–15
clinical subtypes 11
criterion validity 19–21
cultural aspects 21
diagnostic criteria 13–21
diseases and broad syndromes 22–3
endophenotypes 23–4
longitudinal course 10, 12
origin and evolution of schizophrenia 2–9
positive impact and unintended adverse effects 13–14
predictive validity 17–19
reliability 16
revisions of classifications 22
stigma 21
utility in research 15–16
validity 16–21
Diagnostic and Statistical Manual (DSM-V) 21, 153
diffusion tensor imaging (DTI) 40–2
dimensions, classification systems 8–9
diphenhydramine 176
DISC1 see disrupted in schizophrenia 1
disconnection syndrome 31
discrimination 237–8
disorganised symptoms 8–9
disrupted in schizophrenia 1 (DISC1) gene 49, 121
DMXB-A 171, 175
dopamine hypothesis 33, 36
dopamine receptors D2/3/4 (DRD2/3/4) 117
dopamine targets 172–4
dopamine transporter (DAT) 118
DRD2/3/4 see dopamine receptor D2/3/4
DSM see Diagnostic and Statistical Manual
DTI see diffusion tensor imaging
duration of untreated psychosis (DUP) 19, 143
dysbindin (DTNBP1) 37, 115
early recognition of risk 141–154
clinical staging model 150–2
Diagnostic and Statistical Manual criteria 152–4
ethical issues 154
future research directions 155–6
phase-specific treatment 143
prodromal stage 143–9
prognosis and progression of illness 142
psychosis risk syndrome 150–4
screening tools 145
symptom specificity 153–4
therapeutic interventions 146
ultra-high risk criteria 144
ecological approach to rehabilitation 233
ecological validity 81
eicosapentanoic acid (EPA) 149
emotional intelligence 75–6
emotional processing 75–6, 79
encoding 5HT2A receptor 118
endogenous psychoses 5
endophenotypes
classification systems 23–4
early recognition of risk 155
genetics 119
entorhinal cortex cellular disturbances 43–5
environmental factors
classification systems 2
genetics 110, 113
management of schizophrenia 228
EPA see eicosapentanoic acid
epidemiology
diagnosis 110
family, twin and adoption studies 110–11
genetic 111–3, 130
epilepsy 125–9
EPS see extrapyramidal side effects
erythropoietin 51
ethical issues 154
European First Episode Study (EUFEST) 168
extrapyramidal side effects (EPS) 162
facial affect perception 91–5
factor analysis
classification systems 8
neurocognitive and social cognitive impairments 82
false beliefs 79
false-positives 145
family burden 219–20
family studies 8, 17, 21, 110–11
FGA see first generation antipsychotics
fibroblast growth factor receptor 2 (FGFR2) 115
first-episode psychosis 142, 143
first-episode schizophrenia 47–8
INDEX

first generation antipsychotics (FGA) 162
first-rank symptoms (FRS) 6, 18
fMRI see functional magnetic resonance imaging
French psychiatric classifications 5
frontotemporal disturbances 34, 38–40
FRS see first-rank symptoms
functional candidate studies 116–20
functional capacity 51, 71, 82–9
functional domain disturbances 32–3
functional magnetic resonance imaging (fMRI) 40–2
functional outcome
 definitions and characteristics 68
 future research directions 91–5
 integrative models 68
 neurocognitive impairments 71–2
 NIMH-MATRICS initiative 72–4
 social cognitive impairments 80, 81–90
GABA see gamma-butyric acid
galantamine 175–6
gamma-butyric acid (GABA) 36
gender issues 220–1
genetics 109–34
 chromosomal abnormalities 120–1
 classification systems 2, 19–21
 clinical genetic testing 133–4
 copy number variants 120, 126–9
 diagnosis 111–3
 epidemiology 110–3
 family, twin and adoption studies 110–1
 functional candidate studies 116–20
 future research directions 130–4
 genome-wide association studies 114, 121–2
 linkage analysis 114
 mixed economy of genetic variants 133
 pharmacogenetics 133
 positional candidate studies 115–6
 genome-wide association studies (GWAS) 109, 114, 121
GLI see grey-level index
 glutamate agonists 51
 glutamate hypothesis 36–8
 glutamatergic targets 171–2
 glycine transport inhibitors 172
 GNB1L gene 120
 grade of membership (GoM) 9
 grandiose presentations 188
grey-level index (GLI) 43–44
GWAS see genome-wide association studies
haloperidol 33, 50, 165, 168
health care settings 225–7
hebephrenia 3, 6
heritability see genetics
high-throughput genotyping arrays 122
histamine targets 176–8
housing 233–4
HTR2A encoding 5HT2A receptor 118
IAPT see Increasing Access to Psychological Therapies
ICD see International Classification of Diseases
ICD-10 see International Classification of Diseases
ICD-11 see International Classification of Diseases
ICM see intensive case management
illness appraisals 192
iloperidone 169
Increasing Access to Psychological Therapies (IAPT) 202
independent housing 233–4
Individual Placement Model 235
individual-centred rehabilitation 230–1
integrative management approaches 218
intensive case management (ICM) 226
Internal, Personal and Situational Attributions Questionnaire 76, 78
International Classification of Diseases (ICD-10) 10
 clinical relevance and cognitive ease of use 14–5
 clinical subtypes 11
criterion validity 19–21
cultural aspects 21
diagnostic criteria 7, 22
diagnostic validity 16
endophenotypes 23–4
F2 group of disorders 11
origin and evolution of schizophrenia 2–4
pattern of course 11
positive impact and unintended adverse effects 13–14
predictive validity 17–9–2
reliability 16
revisions of classifications 22–3
stigma 21
utility in research 24–5
validity 19–21
International Classification of Diseases (ICD-11) 21
International Classification of Functioning, Disability and Health (ICF) 228
jumping to conclusions (JTC) biases 190
Kraepelin’s clinical forms 3–4, 9
<table>
<thead>
<tr>
<th>INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td>latent class analysis (LCA) 9</td>
</tr>
<tr>
<td>legal problems 223–5</td>
</tr>
<tr>
<td>Leonhard’s endogenous psychoses 5–7</td>
</tr>
<tr>
<td>life events 186–8</td>
</tr>
<tr>
<td>limbic disorders 38–40</td>
</tr>
<tr>
<td>linkage analysis 109, 114</td>
</tr>
<tr>
<td>low intensity CBT 202</td>
</tr>
<tr>
<td>magnetic resonance imaging (MRI) 38</td>
</tr>
<tr>
<td>magnetic transfer imaging (MTI) 40</td>
</tr>
<tr>
<td>maintenance phase 163, 166</td>
</tr>
<tr>
<td>major histocompatibility complex (MHC) 124</td>
</tr>
<tr>
<td>management of schizophrenia 163, 217–20</td>
</tr>
<tr>
<td>burden of care 218–9</td>
</tr>
<tr>
<td>case management 148, 226</td>
</tr>
<tr>
<td>conceptual framework 229–30</td>
</tr>
<tr>
<td>current approaches 230–1</td>
</tr>
<tr>
<td>ecological approach to rehabilitation 233</td>
</tr>
<tr>
<td>gender issues 220–1</td>
</tr>
<tr>
<td>health care settings 225–7</td>
</tr>
<tr>
<td>housing 233–4</td>
</tr>
<tr>
<td>individual-centred rehabilitation 230–31</td>
</tr>
<tr>
<td>integrative approaches 218–20</td>
</tr>
<tr>
<td>International Classification of Functioning, Disability and Health 227–9</td>
</tr>
<tr>
<td>legal problems 223–5</td>
</tr>
<tr>
<td>mental health professional roles 13, 194, 224, 235</td>
</tr>
<tr>
<td>mortality 222–3</td>
</tr>
<tr>
<td>occupational functioning 142, 217</td>
</tr>
<tr>
<td>participation in community life and rights 235–6</td>
</tr>
<tr>
<td>personally recovery tasks 223</td>
</tr>
<tr>
<td>pharmacological interventions 91</td>
</tr>
<tr>
<td>psychosocial interventions 91, 95, 149, 154</td>
</tr>
<tr>
<td>rehabilitation 227–9</td>
</tr>
<tr>
<td>relapse rates 219</td>
</tr>
<tr>
<td>stigma and discrimination 236</td>
</tr>
<tr>
<td>target populations 229</td>
</tr>
<tr>
<td>violent behaviour 199</td>
</tr>
<tr>
<td>MATRICS see Measurement and Treatment Research to Improve Cognition in Schizophrenia</td>
</tr>
<tr>
<td>MATRICS Consensus Cognitive Battery (MCCB) 73</td>
</tr>
<tr>
<td>Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) 76</td>
</tr>
<tr>
<td>MCCB see MATRICS Consensus Cognitive Battery</td>
</tr>
<tr>
<td>Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) 72, 170</td>
</tr>
<tr>
<td>mental state attribution/mentalising see theory of mind</td>
</tr>
<tr>
<td>metabotropic glutamate receptors (MGlur) 172</td>
</tr>
<tr>
<td>metacognitive training 191</td>
</tr>
<tr>
<td>methamphetamine-induced locomotor hyperactivity 177</td>
</tr>
<tr>
<td>MGluR see metabotropic glutamate receptors</td>
</tr>
<tr>
<td>MHC see major histocompatibility complex</td>
</tr>
<tr>
<td>molecular genetics see genetics</td>
</tr>
<tr>
<td>mortality rates 222–3</td>
</tr>
<tr>
<td>MRI see magnetic resonance imaging</td>
</tr>
<tr>
<td>MSCEIT see Mayer-Salovey-Caruso Emotional Intelligence Test</td>
</tr>
<tr>
<td>MTI see magnetic transfer imaging</td>
</tr>
<tr>
<td>N-methyl-D-aspartate (NDMA) receptors 36</td>
</tr>
<tr>
<td>NAA see nicotinergic acetylcholine agonists</td>
</tr>
<tr>
<td>National Institute for Clinical Excellence (NICE) guidelines 162</td>
</tr>
<tr>
<td>NDE1 gene 121</td>
</tr>
<tr>
<td>NDE1 gene 121</td>
</tr>
<tr>
<td>NDMA see N-methyl-D-aspartate</td>
</tr>
<tr>
<td>negative symptoms 11, 32, 40, 90, 112</td>
</tr>
<tr>
<td>neurocognitive impairments 68, 71</td>
</tr>
<tr>
<td>core deficits of schizophrenia 69–71</td>
</tr>
<tr>
<td>definitions and characteristics 67–8</td>
</tr>
<tr>
<td>domains, measurement and magnitude 69</td>
</tr>
<tr>
<td>functional outcome 71–2</td>
</tr>
<tr>
<td>future research directions 22, 48, 75, 129</td>
</tr>
<tr>
<td>integrative models 68</td>
</tr>
<tr>
<td>NIMH-MATRICS initiative 72–4</td>
</tr>
<tr>
<td>pharmacological and psychosocial interventions 67</td>
</tr>
<tr>
<td>social cognitive impairments 74–5</td>
</tr>
<tr>
<td>neurodegenerative hypothesis 46–8</td>
</tr>
<tr>
<td>neurodevelopmental disorders</td>
</tr>
<tr>
<td>pathophysiology of schizophrenia 32–3</td>
</tr>
<tr>
<td>neurogenesis 48–9</td>
</tr>
<tr>
<td>neurogranin (NRGN) gene 124</td>
</tr>
<tr>
<td>neuronal networks</td>
</tr>
<tr>
<td>disconnection syndrome 31</td>
</tr>
<tr>
<td>pathophysiology of schizophrenia 31–2</td>
</tr>
<tr>
<td>neuroplasticity 123</td>
</tr>
<tr>
<td>neurotransmitter disturbances</td>
</tr>
<tr>
<td>dopamine hypothesis 33–6</td>
</tr>
<tr>
<td>glutamate hypothesis 36–7</td>
</tr>
<tr>
<td>pathophysiology of schizophrenia 31–51</td>
</tr>
<tr>
<td>NICE see National Institute for Clinical Excellence</td>
</tr>
<tr>
<td>nicotinergic acetylcholine agonists 51</td>
</tr>
<tr>
<td>nicotinic receptors 175</td>
</tr>
<tr>
<td>NIMH CATIE see Clinical Antipsychotic Trials of Intervention Effectiveness</td>
</tr>
<tr>
<td>NIMH-MATRICS see Measurement and Treatment Research to Improve Cognition in Schizophrenia nonadherence to pharmacological interventions 91</td>
</tr>
</tbody>
</table>
INDEX

non-affective endogenous psychoses 6
non-paranoid schizophrenia 7
non-process schizophrenia 7
non-social cognition see neurocognitive impairments
normalisation 193
Norman-Roberts syndrome 123
NOTCH4 gene 124
NRG1 see neuregulin 1
NRGN see neurogranin
NRXN1 gene 127, 129
occupational functioning 13, 142, 217
olanzapine 146, 166–8
oligodendrocytes 44, 45
omega-3 fatty acids 147
optimal parsing of social cognitive domains 80
outcome see functional outcome
paliperidone palmitate 167
paranoid dementia 3
paranoid schizophrenia 7, 18, 43
Parkinson’s disease 174
pathophysiology of schizophrenia 34–37
antipsychotics 50
disconnection syndrome 31
dopamine hypothesis 33–6
hippocampus and entorhinal cortex 43–5
neurodegenerative hypothesis 46–8
neurodevelopmental disturbances 46–48
neurogenesis 68–9
neuronal networks 38–40
neurotransmitter disturbances 31
prefrontal and temporal cortex 45–6
symptom domains 32–33
thalamus 46
Patient Outcome Research Team (PORT) guidelines 162
PDE4B gene 121
periodic dementia praecox 3
personal goals 201, 229–30
personalising drug treatments 169–70
PET see positron emission tomography
pharmacogenetics 133
pharmacological interventions 91
acute psychotic phase 189, 191–2
cholinergic targets 174–6
cognition 74
dopamine targets 172–4
early recognition of risk 141–2
first-episode schizophrenia 195
glutamatergic targets 171–2
histamine targets 176–8
maintenance phase 166–7
management of schizophrenia 2
negative symptoms 170–1
neurocognitive and social cognitive impairments 67–90
new antipsychotics 195–6
nonadherence 166–7
pathophysiology of schizophrenia 31–50
personalising drug treatments 169–70
phases of schizophrenia 48, 163–7
psychosocial interventions 91–5
stabilization phase 166
therapeutic targets 170–1
treatment resistance 167–8
phase-specific treatment 142–3
Pitt-Hopkins syndrome 125, 127
PORT see Patient Outcome Research Team
positive impact criteria 13–14
positive-negative schizophrenia 7
positron emission tomography (PET) 33, 42
post-traumatic symptoms 188, 199
PPI see prepulse inhibition
predictive validity 17–19
prefrontal cortex cellular disturbances 35, 40, 42
prepulse inhibition (PPI) 24, 33
prevention 143–46
clinical staging model 150–2
Diagnostic and Statistical Manual criteria 2
ethical issues 154
future research directions 48
phase-specific treatment 142–3
prodromal stage 143–6
psychosis risk syndrome 150–4
screening tools 145
symptom specificity 153
therapeutic interventions 141, 147
ultra-high risk criteria 144
primary prevention 142, 155
PRKCA see protein kinase C alpha
procedural criteria 17
process schizophrenia 7
PRODH gene 120
prodromal stage 143–6
Diagnostic and Statistical Manual criteria 2
screening tools 145
symptom specificity 153
therapeutic interventions 141, 147
ultra-high risk criteria 144
Profile of Nonverbal Sensitivity 77, 93
protein kinase C alpha (PRKCA) 115
psychiatric rehabilitation see rehabilitation
psychometric testing 16, 74
psychosis
cognitive behaviour therapy 232
early recognition of risk 141–2
INDEX

French psychiatry 5
neurocognitive impairments 71–2
psychosis risk syndrome 150–2
psychosocial interventions
early recognition of risk 141–2
management of schizophrenia 163, 217
neurocognitive and social cognitive impairments 67, 95
pharmacological interventions 91
rehabilitation 87, 217
see also cognitive behaviour therapy
quality of life (QoL) 71, 90
quetiapine 93, 94, 149, 163, 165, 168
RAND/UCLA Appropriateness Method 73
rare risk alleles 132
RC see residential continuums
RDC see research diagnostic criteria
real-world functioning 82, 90–1
 reappraisal 186
reasoning biases 190–91, 198, 202
recovery-oriented approaches 68
reelins (RELN) 123
regulator of G-protein signalling 4 (RGS4) 115
rehabilitation 71, 90, 166, 217–8, 227–9
burden of care 218–9
conceptual framework 229–30
current approaches 230–1
ecological approach 233
health care settings 225–7
housing 233–4
individual-centred 229, 230–1
International Classification of Functioning, Disability and Health 227–8
mental health professional roles 237–8
neurocognitive and social cognitive impairments 67, 95
occupational functioning 13, 142, 217
participation in community life and rights 235–6
pharmacological interventions 91
psychosocial interventions 67, 91, 95, 142, 149, 217–8
stigma and discrimination 235–6, 237
target populations 229
relapse rates 220
reliability 16
RELN see reelins
remediation exercises 91
research diagnostic criteria (RDC) 7
residential continuums (RC) 233–4
RGS4 see regulator of G-protein signalling 4
risk syndrome see psychosis risk syndrome
risperidone 50, 146, 148, 163–9
safety behaviours 192
sarcosine 172
Scale of Prodromal Symptoms (SOPS) 145
Schema Comprehension Sequencing
Test-Revised 78
schematic beliefs 187–8
schizoaffective disorder 8–9, 18, 20
schizophrenia 3
schizophrenia risk syndrome 2
schizophrenia-spectrum psychosis 186
schizophreniform psychoses 7
schizotypal disorder 8
schizotypal personality disorder (SPD) 8
Schneider’s first-rank symptoms 6, 10, 18
SE see supported employment
second generation antipsychotics (SGA) 162
secondary morbidities 142
secondary prevention 142
self-determination 230, 237
serotonin transporter gene 118
SGA see second generation antipsychotics
sheltered housing 233–4
short stature homeobox isoform b (SHOX) 123
single-gene disorders 114
single nucleotide polymorphisms (SNP) 122, 170
single-photon emission computed tomography (SPECT) 42
SIPS see Structured Interview for Prodromal Symptoms
SLC6A3 dopamine transporter 118
SLC6A4 serotonin transporter gene 118
SNAP-25 see synaptosome-associated protein 25
SNARE see soluble N-ethylmaleimide-sensitive factor attachment protein receptor
SNP see single nucleotide polymorphisms
social cognitive impairments 67–95
attributional bias 78, 190
core features of schizophrenia 68–9
current research directions 72–4
domains, measurement and magnitude 69, 75
emotional processing 75–6, 79
functional outcome 71–2, 81–90
future research directions 91–5
integrative models 68
neurocognitive impairments 68–74
NIMH-MATRICS initiative 72–4
social knowledge 77–8
social perception 77, 79, 90, 95
target populations 229
target populations 229
theory of mind 78–9, 191
Social Cue Recognition Test 77
Social Features Recognition Test 78
social integration 218, 221, 235–6
social knowledge 77–8
INDEX

social perception 77, 79, 90, 95
social skills training 232–3
soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) 49
SOPS see Scale of Prodromal Symptoms
SPD see schizotypal personality disorder
SPECT see single-photon emission computed tomography
stabilization phase 166
stereology studies 43–5
stigma
classification systems 229
eyard recognition of risk 154
rehabilitation 227–9
Structured Interview for Prodromal Symptoms (SIPS) 145
substance abuse 168, 223–5
suicidality 231
supported employment (SE) 235
supportive therapy 148–9, 154
symptom domains 32–8
synaptic plasticity 51
synaptic pruning 47–8
synaptogenesis 48–50
synaptosome-associated protein 25 (SNAP-25) 49
systematic schizophrenias 5
SzGene database 116

TBX1 gene 120
TCF4 gene 125
temporal cortex cellular disturbances 45–6
thalamus cellular disturbances 46
theory of mind (ToM) 78–9, 191
tolcapone 174
ToM see theory of mind

trait and state risk factors 144
transition to psychosis 149
trauma 188–9
treatment costs 225
Treatment Units for Research on Neurocognition and Schizophrenia (TURNS) 91
tropisetron 175
TURNS see Treatment Units for Research on Neurocognition and Schizophrenia
twin studies 110–11
type II diabetes 126, 133
ultra-high risk (UHR) criteria 144–6
unintended adverse effects 13–14
unsystematic schizophrenias 5
utility in research 15–16

validity 16–19
valine-to-methionine variant (Val/Met) 119
VAMP see vesicle protein synaptobrevin
velocardiofacial syndrome (VCFS) 120–21
vesicle protein synaptobrevin (VAMP) 49
violent behaviour 199
vocal affect perception 92
vocational rehabilitation see occupational functioning

weight monitoring 223
World Health Organization (WHO) 227
see also International Classification of Diseases
ziprasidone 163, 165, 168
ZNF804A gene 123–4
zotepine 163